Immunic (NASDAQ:IMUX) posted its quarterly earnings data on Thursday. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.15), Fidelity Earnings reports.
IMUX stock traded down $0.35 during mid-day trading on Friday, reaching $8.01. The company had a trading volume of 18,900 shares, compared to its average volume of 126,712. The stock has a market cap of $86.77 million, a P/E ratio of -0.23 and a beta of 3.51. The business has a 50 day moving average of $9.77. Immunic has a 12 month low of $6.00 and a 12 month high of $46.80.
A number of research firms recently weighed in on IMUX. Zacks Investment Research raised shares of Immunic from a “sell” rating to a “hold” rating in a research report on Wednesday, October 30th. Chardan Capital reissued a “buy” rating on shares of Immunic in a research report on Thursday, September 19th. Finally, ValuEngine raised shares of Immunic from a “hold” rating to a “buy” rating in a research report on Saturday, October 5th.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
See Also: Google Finance Portfolio Workaround
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.